Diabetes
The following areas are of research interest:
- Prediabetes and pathophysiology
- Role of Linagliptin in early clinical dysglycaemia
- Explore biological pathways of different tissues
- Patients and care
- Experience out of daily therapeutic routine in special populations and patient settings
- Compliance/adherence
- Incretin effects:
- General and specific effects
- DPP-4 Inhibition
- Pathophysiology and biopathways
- Transfer into clinical reality
- Renal, cardiovascular and further complications of diabetes
- Excretion via the kidney (MA)
- Renocardial axis
- α-Cell and β-cell functions
- Biomarker
- Pathophysiology
- (Im)balance of glucagon and insulin
Prior to submission, please contact the BIPI Medical IIS Office by calling 877-757-7354 for more information and assistance.
After you contact the BIPI Medical IIS Office researchers or physicians must submit a preliminary proposal. In order for BIPI to determine interest in the IIS concept, the following information will be required in the proposal:
- Full title of the study
- Name and contact of principle investigator
- Study rationale
- Study objectives
- Study design
- Statistical methods
- Data Management Plan/System
- Requested Support (Drug, Funding or both)
- Drug Supply Request (BIPI Drug and/or non-BIPI Drug)
- Preliminary Budget (incl. Direct, Indirect Costs and Fees)
Submission of a preliminary Proposal does not imply or guarantee approval. All proposals will be reviewed based on scientific merit and available funding.
Investigators outside of the United States interested in Diabetes IIS are encouraged to visit http://www.boehringer-ingelheim.com/clinical_trials/iis_diabetes.html.
To contact Boehringer Ingelheim Pharmaceuticals, Inc., Medical IIS Office, please call 877-757-7354.
